IceCure Medical Welcomes Meir Peleg as Chief Financial Officer to Drive Growth

IceCure Medical Appoints Meir Peleg as CFO

In a significant move to bolster its financial leadership, IceCure Medical Ltd. (NASDAQ: ICCM), a pioneering company in minimally invasive cryoablation technologies, has announced the appointment of Meir Peleg as its Chief Financial Officer (CFO) effective May 17, 2026. Peleg’s extensive experience, spanning over two decades, particularly in the financial sectors of public companies, coupled with his engineering background, positions him as a valuable asset for IceCure as the company accelerates its growth trajectory.

Background on Meir Peleg

Meir Peleg is known for his remarkable track record in the financial realm, having successfully overseen multiple large-scale capital raises and a Nasdaq IPO. His unique skill set, which merges financial acumen with a technical background, allows him to bring a systematic, data-driven approach to financial governance. As a Certified Public Accountant, Peleg has held pivotal roles that focus on maximizing shareholder value and guiding companies through their growth phases.

In his new position at IceCure, Peleg will be instrumental in supporting the company as it builds upon the strong commercial momentum of its flagship product, ProSense®, which has recently received FDA clearance for low-risk breast cancer treatment. This product offers patients an innovative alternative to traditional surgical options by employing cryoablation to destroy tumors through freezing.

ProSense® and Market Dynamics

IceCure’s ProSense® Cryoablation System represents a cutting-edge solution, recognized for its effectiveness and safety in treating various tumors, including those associated with breast cancer. The technology not only offers minimal invasiveness but is also designed to enhance patient recovery by reducing pain and surgical risks. Hence, ProSense® not only contributes to the clinical landscape but also captures significant market interest following its FDA approval.

CEO Eyal Shamir expressed enthusiasm about Peleg joining the leadership team at this pivotal moment, emphasizing the importance of his experience in navigating the complexities involved in scaling a rapidly growing operation. Under Peleg’s guidance, IceCure aims to capitalize on its market acceptance and push forward with a clear strategic vision throughout the company.

Future Steps for IceCure Medical

As part of IceCure's growth strategy, the company is also looking to enhance its medical team by appointing Dr. Richard E. Fine, a recognized surgeon and expert in breast oncology, as their Medical Director. This strategic addition will further underpin IceCure's commitment to advancing cryoablation education and clinical initiatives, particularly for low-risk breast cancer patients.

Moreover, the company is searching for a new Chief Technology Officer to align its technical capacities with its ambitious healthcare goals. With These appointments poised to solidify IceCure's leadership in the industry, the company is gearing up for continued expansion both in the U.S. market and globally.

Conclusion

Meir Peleg’s appointment symbolizes a crucial step for IceCure as it strives to broaden its impact in the fields of oncology and cryoablation technology. With a strong financial foundation and strategic leadership in place, IceCure is now better equipped to navigate the challenges of the healthcare landscape while delivering innovative solutions that meet the needs of patients globally. This reflects not just a strategic move but a renewed commitment to making significant strides in medical technology and patient care.